Moderna, Inc. (ETR:0QF)
21.37
-0.37 (-1.70%)
At close: Sep 19, 2025
Moderna Revenue
Moderna had revenue of $142.00M USD in the quarter ending June 30, 2025, a decrease of -41.08%. This brings the company's revenue in the last twelve months to $3.08B, down -39.05% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$3.08B
Revenue Growth
-39.05%
P/S Ratio
3.19
Revenue / Employee
$530.69K
Employees
5,800
Market Cap
8.36B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Sartorius Aktiengesellschaft | 3.47B |
Fresenius Medical Care AG | 19.52B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Moderna News
- 1 day ago - CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids - Investor's Business Daily
- 1 day ago - Notable Friday Option Activity: MRNA, NKE, FLNC - Nasdaq
- 1 day ago - Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Wallstreet:Online
- 1 day ago - Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Accesswire
- 1 day ago - Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
- 1 day ago - Moderna (MRNA) Settles Patent Dispute with Alnylam - GuruFocus
- 1 day ago - Moderna, Alnylam settle patent row over COVID vaccine delivery technology - Seeking Alpha
- 2 days ago - The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut - Investor's Business Daily